Treatment with a PCSK9 inhibitor is well tolerated and improves cardiovascular outcomes .
Although no overall benefit was noted in all-cause or cardiovascular mortality , such benefit may be achievable in patients with higher baseline low-density lipoprotein cholesterol
BACKGROUND We sought to examine the efficacy and safety of 2 PCSK9 ( proprotein convertase subtilisin/kexin type 9 ) inhibitors : alirocumab and evolocumab .
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Observational studies have given conflicting results about the effect of statins in preventing  dementia and cognitive decline . Moreover , observational studies are subject to prescription bias , making it hard to draw definite conclusions from them . R and omized controlled trials are therefore the preferred study design to investigate the association between statins and cognition . Here we present detailed cognitive outcomes from the r and omized placebo-controlled PROspect i ve Study of  Pravastatin in the Elderly at Risk ( PROSPER ) . Cognitive function was assessed repeatedly in all 5,804 PROSPER participants at six different time points during the study using four neuropsychological performance tests . After a mean follow-up period of 42 months , no difference in cognitive decline at any of the cognitive domains was found in subjects treated with pravastatin compared to placebo ( all p > 0.05 ) . Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period . Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile
Treatment with a PCSK9 inhibitor is well tolerated and improves cardiovascular outcomes .
Although no overall benefit was noted in all-cause or cardiovascular mortality , such benefit may be achievable in patients with higher baseline low-density lipoprotein cholesterol
BACKGROUND We sought to examine the efficacy and safety of 2 PCSK9 ( proprotein convertase subtilisin/kexin type 9 ) inhibitors : alirocumab and evolocumab .